Kelowna, British Columbia – October 16, 2025 – TheNewswire - Rize Oncology Inc. (the “Company”), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, today announced the resignation of Daren Graham as Executive Chairman and interim Chief Executive Officer of the Company.   P. Gage Jull, a current Director of the Company, has been appointed the Company’s interim Chief Executive Officer.  It is anticipated that Mr. Jull’s appointment will be for a limited period while the Board of Directors evaluates potential candidates to fill the position permanently.

About Rize Oncology Inc.

Rize Oncology Inc. is a clinical-stage biopharmaceutical company dedicated to the development of STS-201, a small-molecule drug with a unique mechanism of action, currently being evaluated for its potential in treating soft tissue sarcoma and other cancers.​

Contact:

P. Gage Jull

416-562-7525

gagejull1@gmail.com

Forward-Looking Statements

This news release contains statements that constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Forward-looking statements in this document include the Company’s expectation that Mr. Jull’s appointment will be on an interim basis, that a permanent Chief Executive Officer will be engaged and all other statements that are not statements of historical fact.

Although the Company believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.

Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with general economic conditions; adverse industry events; future legislative and regulatory developments; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of the Company to implement its business strategies; competition; the ability of Rize to obtain and retain all applicable regulatory and other approvals and other assumptions, risks and uncertainties that may be disclosed in the Company’s continuous disclosure record from time to time.